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BACKGROUND: No standard treatment for locally advanced pancreatic cancer (LAPC) is defined.
PATIENTS AND METHODS: Within a multi-centre, randomised phase II trial, 95 patients with LAPC were assigned to three different
chemoradiotherapy (CRT) regimens: patients received conventionally fractionated radiotherapy of 50Gy and were randomised to
concurrent 5-fluorouracil (350mgm
 2 per day on each day of radiotherapy, RT-5-FU arm), concurrent gemcitabine (300mgm
 2),
and cisplatin (30mgm
 2) on days 1, 8, 22, and 29 (RT-GC arm), or the same concurrent treatment followed by sequential full-dose
gemcitabine (1000mgm
 2) and cisplatin (50mgm
 2) every 2 weeks (RT-GCþGC arm). Primary end point was the overall survival
(OS) rate after 9 months.
RESULTS: The 9-month OS rate was 58% in the RT-5-FU arm, 52% in the RT-GC arm, and 45% in the RT-GCþGC arm.
Corresponding median survival times were 9.6, 9.3, and 7.3 months (P¼0.61) respectively. The intent-to-treat response rate was 19,
22, and 13% respectively. Median progression-free survival was estimated with 4.0, 5.6, and 6.0 months (P¼0.21). Grade 3/4
haematological toxicities were more frequent in the two GC-containing arms, no grade 3/4 febrile neutropaenia was observed.
CONCLUSION: None of the three CRT regimens tested met the investigators’ definition for efficacy; the median OS was similar to those
previously reported with gemcitabine alone in LAPC.
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Pancreatic adenocarcinoma remains a disease with a dismal
prognosis: in 2008, 37680 estimated new cases were diagnosed in
the United States, with a nearly identical rate of estimated deaths
(34290) from pancreatic cancer (Jemal et al, 2008). Since the
introduction of the nucleoside analogue gemcitabine, several phase
III trials have evaluated the role of a gemcitabine-containing
combination treatment for advanced pancreatic cancer (Burris
et al, 1997; Hochster et al, 2006). So far, only the combination of
gemcitabine with the anti-EGFR tyrosine kinase inhibitor erlotinib
provided a survival benefit compared to single-agent gemcitabine
(Moore et al, 2007). Promising efficacy results were also obtained
with cytotoxic combinations of gemcitabine in combination with
capecitabine or a platinum analogue (Cunningham et al, 2005;
Louvet et al, 2005; Heinemann et al, 2006, 2008; Herrmann et al,
2007).
Most of the palliative phase III trials that were conducted during
the last decade included both patients with non-resectable locally
advanced pancreatic cancer (LAPC) and metastatic pancreatic
cancer. However, based on post hoc subgroup analyses it became
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sevident that LAPC may be characterised by a different disease
biology than metastatic pancreatic cancer: patients with LAPC
showed a prolonged survival (about 10 months) and in several
studies, they obtained no survival benefit from combination
chemotherapy (compared to gemcitabine alone) (Louvet et al,
2005; Heinemann et al, 2006). Chemoradiotherapy (CRT) also has
been investigated widely in patients with LAPC; McGinn et al
(2001) were among the first to introduce gemcitabine in CRT
protocols for LAPC treatment. Subsequently, several other groups
also conducted phase I and II clinical trials to improve CRT
protocols for LAPC by including newer cytotoxic agents such
as gemcitabine, cisplatin, or oxaliplatin as concurrent radio-
sensitising agents in their radiotherapy regimens (Desai et al,
2007; Haddock et al, 2007; Hong et al, 2008; Small et al, 2008).
More recently, the final results from the first randomised trial
comparing systemic chemotherapy alone with CRT (followed
by maintenance chemotherapy) in LAPC were reported by
Chauffert et al (2008): overall survival (OS), the primary study
end point, was shorter in the CRT arm (8.6 months) than in the
gemcitabine chemotherapy arm (13 months, P¼0.03; Chauffert
et al, 2008). In contrast, the preliminary results of a phase III
trial (E4201) comparing gemcitabine in combination with radio-
therapy vs gemcitabine alone in LAPC suggested a survival
benefit for patients in the radiotherapy arm (11 vs 9.2 months).
However, this study with 74 patients was terminated prematurely
due to low accrual (targeted sample size, 316), and significant
grade 3/4 toxicities were observed in both the arms (Loehrer et al,
2008).
The purpose of this three-arm, randomised phase II trial was to
exploratively compare three different CRT regimens in terms of
efficacy and tolerance in the treatment of patients with LAPC. A
5-fluorouracil (5-FU)-based CRT protocol was selected as refer-
ence arm, whereas patients in the two other treatment arms
received CRT with concurrent low-dose gemcitabine and cisplatin.
These two cytostatic agents were selected on the basis that both
are known to exert their effect as potent radiosensitisers in
pancreatic cancer and both agents are also known to be effective in
patients with metastatic disease. In one treatment arm, patients
also received sequential full-dose chemotherapy with gemcitabine/
cisplatin (in analogy to Heinemann et al, 2006) after completion of
concurrent gemcitabine/cisplatin-based CRT to improve systemic
disease control.
PATIENTS AND METHODS
Patient population
Male or female patients between 18 and 75 years of age with
histologically confirmed, non-resectable pancreatic cancer (stages
III and IVA) were eligible for this phase II study. Non-resectability
criteria included at least one of the following CT findings: nodal
involvement; retroperitoneal infiltration; infiltration of the arteria
mesenterica superior, vena mesenterica superior, arteria hepatica,
or portal vein. At least one bi-dimensionally measurable lesion had
to be present. Exclusion criteria included distant metastasis and
previous radiotherapy of the abdominal region. The following
patients were also excluded: pregnant or lactating patients, women
of childbearing potential who lacked a reliable contraceptive
method, patients with poor performance status (KPS o70%),
insufficient renal function (creatinine clearance o80mlmin
 1),
and active infections. Patients who participated in another
experimental clinical trial within 6 weeks of the start of treatment
were ineligible. Adequate bone marrow reserve was required:
WBC, X3.5 10
9l
 1; platelet count, X100 10
9l
 1; haemoglobin,
X100gl
 1. The study was approved by the ethical committees
of all participating German centres and each patient gave
written informed consent before any study-specific procedure.
This study was conducted according to the Declaration of Helsinki
Principles.
Study design and treatment
In this explorative phase II trial the patients were randomised in a
1:1:1 ratio to the three treatment arms, after stratification for
performance status and centre. The primary objective of the study
was to determine the anti-neoplastic efficacy of the combined
modality regimens, primarily about the OS rates at 9 months after
randomisation. This specific 9-month interval was selected as the
study committee expected a minimum median survival time of 9
months for LAPC patients treated with CRT. Secondary objectives
included the achievement of secondary resectability, progression-
free survival (PFS), response rate, and toxicity.
External beam irradiation according to CT or MRT image-based
three-dimensional planning was administered on 5 days per week
at a daily dose of 2.0Gy to the first-order target volume (primary
tumour with a 1cm margin) and of 1.8Gy to the second-order
target volume (regional lymph node (LN) areas with a 2–3cm
margin). Thus, the total planned dosages were 50 and 45Gy
respectively. In the reference arm, concurrent 5-FU was given as a
24h continuous infusion of 350mgm
 2 per day on each day of
radiotherapy (RT-5-FU arm). In the experimental CRT arm
300mgm
 2 gemcitabine and 30mgm
 2 cisplatin were adminis-
tered i.v. on days 1, 8, 22, and 29 (ie on the first day of irradiation
weeks 1, 2, 4, and 5), 1h before start of radiotherapy (RT-GC arm).
In the trial arm that included sequential systemic chemotherapy
(RT-GCþGC arm), patients without disease progression after
gemcitabine/cisplatin-based CRT (analogous to RT-GC) received
gemcitabine (1000mgm
 2 over 30min) and cisplatin (50mgm
 2)
every 2 weeks until disease progression, resectability of the
tumour, or unacceptable toxicity.
If necessary, protocol-defined dose reductions were performed
according to clinical and laboratory parameters. Supportive
treatment (e.g. anti-emetic therapy) was administered according
to local standards of the participating centres.
Efficacy and tolerance evaluation
Pre-treatment evaluation included complete history and physical
examination, assessment of performance status and disease
symptoms, a helical CT of the abdomen with assessment of the
tumour size, and an MRI of the liver. Regularly performed
laboratory tests included blood counts, creatinine, liver enzymes,
total bilirubin, alkaline phosphatase, total protein, albumin, CEA,
and CA19-9. A re-staging by CT scan was performed 10 weeks after
the start of radiotherapy and every 3 months thereafter. Remission
or progression of the tumour was defined according to standard
WHO criteria. Objective responses had to be confirmed by a
second CT performed at least 4 weeks after the initial finding
suggesting tumour regression.
For the determination of PFS and OS, all patients were
randomised according to the protocol inclusion and exclusion
criteria were included (intent-to-treat analysis). Toxicity was
classified according to the National Cancer Institute Common
Toxicity Criteria (NCI-CTC), version 2.0. All non-haematological
adverse events were assessed according to the NCI-CTC grading
system in this trial. In addition, acute toxicity (haematological and
non-haematological) during concurrent CRT was also assessed
using standard RTOG toxicity criteria.
Statistical analyses
Based on the available data for the efficacy of standard treatment, a
survival rate of 60% after 9 months was expected after 5-FU-based
CRT in the reference arm. Thus, the experimental regimens with
gemcitabine and cisplatin to be tested in this trial would be
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sconsidered to be not sufficiently active, if the 9-month survival rate
was lower than 60%, but promising in case of a 9-month survival
of X80%. According to these assumptions and to achieve a power
of 90% and a type I error of 0.05, an optimal two-stage design by
Simon required a sample size of 19 evaluable patients per study
arm in the first stage. In this original design, the survival of at least
13 out of these 19 patients would have allowed to enter stage two in
the respective arm, then recruiting further cases up to 53 per arm.
Otherwise, the arm was to be closed for futility. To account for
possible dropouts, we strived for a total number of 60 patients in
each arm. Descriptive statistical methods including confidence
intervals were used throughout the analysis. P-values presented in
this report are explorative in nature and result from two-sided
hypothesis tests.
As a matter of fact, none of the treatment arms reached the goal
described above after the first step. However, as no promising
alternatives for the treatment of LAPC were available at that point
of time, the study committee decided to recruit another 30 patients
to allow for a more precise estimate of efficacy and tolerability.
RESULTS
Patient characteristics
Between February 2002 and July 2005, 95 patients from 12 German
centres were enrolled in this study; the database was closed for
final analysis in August 2008. A CONSORT diagram of the trial is
shown in Figure 1. One patient was classified as non-evaluable, as
no study documentation was available, and one patient was lost to
follow-up immediately after randomisation. Baseline patient
characteristics are summarised in Table 1. Most patients had cT4
tumours, the highest rate of nodal involvement (Nþ) was
observed in the RT-5-FU group (77%). However, in the RT-5-FU
arm, 58% of randomised patients had a good performance status,
whereas only 39% of patients in the RT-GCþGC arm had a KPS of
90–100%. Most of the pancreatic tumours were histologically
classified as adenocarcinomas (about 85%); the remaining
histologies were adenosquamous carcinoma and mucinous carci-
noma. The most frequent reasons for non-resectability of the
primary tumour in the pancreas were suspected LN involvement
(peri-pancreatic LN, 39%; mesenterial LN, 23%; interaortocaval
LN, 10%; liver hilus LN, 10%), vascular involvement (83%), and
retroperitoneal involvement (13%).
Treatment
Radiotherapy The median duration of radiotherapy was 37 days
(range, 5–98) in all patients (RT-5-FU, 37 days; RT-GC, 36 days;
RT-GCþGC, 36 days). The median cumulative radiation dose to
the first-order target volume was 50Gy in each of the three
treatment arms (range for all patients, 9–52). A dose reduction of
radiotherapy was performed in 3% of the patients; in 5% of
patients radiation treatment was delayed at least once during the
course of the study.
Chemotherapy Regarding the concurrent chemotherapy during
radiation, gemcitabine dose reductions had to be performed in
19% of the patients in the RT-GC arm and in 39% of patients in the
RT-GCþGC arm. The corresponding rates for cisplatin dose
reductions were 19% (RT-GC) and 39% (RT-GCþGC) respec-
tively. A dose reduction of concurrent 5-FU was necessary in 4% of
the patients treated in the RT-5-FU arm. The main reasons for
treatment postponement or dose reduction of concurrent chemo-
therapy were (based on 513 treatment cycles) organisational
reasons (39 cycles, 8%), haematological toxicity (23 cycles, 4%),
and non-treatment-related adverse events (16 cycles, 3%) respec-
tively. Of the 31 patients randomised to RT-GCþGC, 6 (19%)
received no sequential chemotherapy with gemcitabine and
cisplatin; 6 (19%) received one cycle GC, 16 (52%) received two
cycles, and 1 patient each (3%) three, four, and six cycles of GC.
The main reasons for termination of treatment were regular
end of study therapy (44 patients, 47%), progressive disease (21
patients, 23%), death (12 patients, 13%), and wish of the patient
(6%). In four patients (4%) study treatment was terminated
because of an adverse event.
Efficacy results
Response by imaging criteria and (secondary) resectability Detailed
results for objective response and resectability after CRT are
summarised in Table 2. Overall, 70 patients were evaluable for
objective response according to WHO criteria. Based on an intent-
to-treat analysis, the overall response rate was 19% in the RT-5-FU
Patients randomised
n = 95
-  Non-eligible due to violation of
   inclusion criteria (n = 1)
- Lost for follow-up (n = 1)
RT-GC
n = 32
RT-GC+GC
n = 31
RT-5FU
n = 30
Evaluable for
PFS and OS
n = 93  
Evaluable for
toxicity
n = 87
RT-5FU
n = 29
RT-GC
n = 31
RT-GC+GC
n = 27
Patients not receiving
treatment per
protocol (n = 6)
- Consent withdrawn
   (n=2)
- Treatment within
   another study
   protocol (n=1)
- No documentation
   of toxicity data n=3)
Figure 1 CONSORT diagram.
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sarm, 22% in the RT-GC arm, and 13% in patients randomised to
RT-GCþGC. Eighteen patients (19%) underwent a secondary
operation after completion of study treatment; in eight of them, a
R0 resection was achieved, four patients showed a microscopically
positive resection margin (R1).
Survival results Progression-free survival: after a median follow-
up of 8.6. months (range, 1.4–39.5), the median PFS was estimated
with 4.0 months in the RT-5-FU arm, 5.6 months in the RT-GC
arm, and 6.0 months in the RT-GCþGC arm (P¼0.21; Table 3).
The Kaplan–Meier plot for PFS is shown in Figure 2A.
Overall survival: at the time of final analysis, 82 of the 93
patients (88%) that were evaluated for OS had died. Median OS
for patients randomised to RT-5-FU was 9.6 months, for patients
randomised to RT-GC 9.3 months, and for patients randomly
assigned to RT-GCþGC 7.3 months (Table 3). The corresponding
9-month OS rates were 58% (RT-5-FU), 52% (RT-GC), and 45%
(RT-GCþGC) respectively (P¼0.61). Figure 2B shows the
Kaplan–Meier plot for OS.
Tolerance results
RTOG acute toxicity during concurrent CRT The acute toxicities
during CRT (according to RTOG and NCI-CTC criteria) in each
treatment arm are summarised in Table 4. Myelosuppression was
more frequent with the two gemcitabine/cisplatin-containing CRT
regimens, with leukocytopaenia and thrombocytopaenia being the
most frequently observed haematological toxicity; no grade 3/4
febrile neutropaenia occurred. Classified according to RTOG
criteria, grade 3/4 upper gastrointestinal (GI) tract toxicity was
also more frequent in the two gemcitabine/cisplatin-based arms
than in the RT-5-FU arm.
Non-haematological toxicity A higher rate of nausea (all grades)
was detected in the cisplatin-containing treatment arms (see
Table 4). The rate of grade 3/4 infections (others than febrile
neutropaenia) was low in all three arms, with 7% (RT-5-FU), 3%
(RT-GC), and 0% (RT-GCþGC) respectively. In the study arm
that contained a sequential chemotherapy with full-dose gemcita-
bine together with cisplatin (RT-GCþGC), the most frequent
non-haematological grade 3/4 toxicities during maintenance
chemotherapy were nausea (8%), vomiting (4%), fatigue (4%),
and infection without neutropaenia (4%).
DISCUSSION
During the last years, LAPC has been increasingly recognised as a
separate disease entity with specific biological features (Hochster
et al, 2006). There is a scientific rationale to treat these patients
with a combined modality approach: for example radiotherapy for
local disease control and chemotherapy for distant disease control.
The radiosensitiser 5-FU has been regarded as a standard agent for
concurrent CRT in several GI malignancies, including pancreatic
Table 2 Efficacy results: objective response rates by WHO criteria and
secondary tumour resection (intention-to-treat analysis)
RT-5-FU
(n¼31)
RT-GC
(n¼32)
RT-GC+GC
(n¼31)
No. (%) No. (%) No. (%)
Response
Complete response 0 (0) 2 (6) 0 (0)
Partial response 6 (19) 5 (16) 4 (13)
Stable disease 5 (16) 11 (34) 10 (32)
Disease control rate
a 11 (35) 18 (56) 14 (45)
Progressive disease 12 (39) 9 (28) 6 (19)
Not assessable 8 (26) 5 (16) 11 (35)
Secondary resection
Yes 4 (13) 8 (25) 6 (19)
No 27 (87) 24 (75) 25 (81)
Abbreviations: 5-FU¼5-fluorouracil; C¼cisplatin; G¼gemcitabine; RT¼radiotherapy.
aDisease control rate¼rate of complete responseþpartial responseþstable disease.
Table 1 Baseline patient and tumour characteristics (n¼94)
RT-5-FU RT-GC RT-GC+GC
Characteristic No. (%) No. (%) No. (%)
Evaluable patients 31 32 31
Age (years)
Median 63 63 65
Range 42–74 40–75 41–75
Sex
Male 15 (48) 16 (50) 20 (65)
Female 16 (52) 16 (50) 11 (35)
T stage
T2 1 (3) — —
T3 7 (23) 8 (25) 8 (26)
T4 23 (74) 24 (75) 23 (74)
N stage
N0 5 (16) 12 (38) 12 (39)
N1 24 (77) 20 (62) 17 (55)
Nx 2 (6) — 2 (6)
Performance status
KPS 70–80% 12 (39) 15 (47) 17 (55)
KPS 90–100% 18 (58) 15 (47) 12 (39)
Missing 1 (3) 2 (6) 2 (6)
Primary tumour site
Head 25 (81) 22 (69) 20 (65)
Body 6 (19) 6 (19) 6 (19)
Tail — 1 (3) 2 (6)
Overlapping — 3 (9) 3 (10)
Adenocarcinoma 27 (87) 27 (84) 27 (87)
Histological degree of tumour differentiation
G1 2 (6) 3 (9) 1 (3)
G2 9 (29) 13 (41) 15 (48)
G3 13 (42) 11 (34) 11 (35)
Unknown 7 (23) 5 (16) 4 (13)
Abbreviations: 5-FU¼5-fluorouracil; C¼cisplatin; G¼gemcitabine; KPS¼Karnofsky
performance status; RT¼radiotherapy.
Table 3 Efficacy results: PFS and OS (intention-to-treat analysis)
RT-5-FU
(n¼30)
RT-GC
(n¼32)
RT-GC+GC
(n¼31)
Median PFS (months) 4.0 5.6 6.0
95% CI 3.5–6.2 4.4–8.5 4.8–11.9
Median OS (months) 9.6 9.3 7.3
95% CI 8.5–11.1 7.3–12.2 5.3–15.2
9-month OS rate (%) 58 52 45
95% CI 43–80 37–74 31–67
18-month OS rate (%) 11 11 22
95% CI 4–32 4–31 11–43
Abbreviations: 5-FU¼5-fluorouracil; C¼cisplatin; CI¼confidence interval; G¼gemcitabine;
OS¼overall survival; PFS¼progression-free survival; RT¼radiotherapy.
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scancer, for several decades. Based on ‘chemotherapy only’ trials, a
median survival of about 9–10 months can be expected for
patients with LAPC that receive single-agent gemcitabine (Louvet
et al, 2005; Heinemann et al, 2006). After gemcitabine was
established as a standard of care in the palliative treatment of
pancreatic cancer (Burris et al, 1997), several phase I/II trials were
initiated to define the role of gemcitabine-based/-containing CRT
for LAPC. Table 5 summarises selected phase II and III clinical
trails (including the current study) that were conducted in LAPC
and included gemcitabine and/or cisplatin in their treatment
protocol. It becomes evident that various treatment approaches
were investigated in these different trials: some studies applied
concurrent low-dose gemcitabine and/or cisplatin as radiosensi-
tisers, whereas others applied full-dose gemcitabine concurrently
to radiotherapy. Although some studies also offered sequential
full-dose chemotherapy after completion of CRT others did not.
Thus the efficacy and tolerance of these different regimens can
only be compared with several limitations.
This trial is the first to compare the efficacy and tolerance of
three different CRT protocols in the treatment of LAPC: based on
several efficacy end points (e.g. response rate, PFS, OS), RT-GC
and RT-GCþGC were not distinctly superior compared with the
reference arm RT-5-FU in this randomised phase II study. As
expected, an increased haematological toxicity was observed in the
two experimental arms, which was clinically manageable for both
regimens (RT-GC and RT-GCþGC). Even if a comparison of
survival results between different clinical trials is rejected as not
appropriate, there is – at least to date – no clear scientific evidence
to support the superiority of CRT compared with chemotherapy-
only in LAPC. In this study, median OS times ranged between 7.3
months (RT-GCþGC) and 9.6 months (RT-5-FU). This observa-
tion is confirmed by the final results of a randomised trial that
compared an intensive induction CRT (with concurrent 5-FU and
cisplatin) followed by sequential full-dose gemcitabine with
gemcitabine-only in LAPC: in this phase III study, patients in
the CRT arm lived even shorter than patients treated with standard
gemcitabine monochemotherapy (Chauffert et al, 2008). One
explanation for this unexpected observation may be based on the
fact that patients initially treated with CRT on that trial received
significantly lower doses of sequential gemcitabine than patients in
the single-agent gemcitabine arm (possibly associated with a
significant haematological toxicity related to induction CRT).
Based on the data reported here, it remains unclear if
gemcitabine can be regarded as a more effective radiosensitising
agent compared to 5-FU in CRT regimens for LAPC. A previous
randomised study by Li et al (2003) found early evidence for an
improved time to progression and OS with the use of concurrent
single-agent gemcitabine compared to 5-FU; however, this small
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Figure 2 (A) Progression-free survival by treatment arm. (B) Overall survival by treatment arm. Abbreviations: 5-FU, 5-fluorouracil; C, cisplatin;
G, gemcitabine; RTX, radiotherapy.
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sstudy conducted in an Asian patient population used a different
5-FU bolus CRT regimen, and thus these results should only be
compared carefully with the current trial. One limitation of this
randomised phase II trial arises from the fact that an analysis of
patterns of treatment failure (local vs distant) was not included.
Specifically the prevention of local failure with the use of effective
CRT should be regarded as an important palliative treatment goal
in patients with LAPC.
Novel treatment concepts in LAPC are, for example, based on a
‘biological’ patient selection by systemic induction chemotherapy.
Two study groups recently reported data on such an approach,
where all LAPC patients receive initial systemic chemotherapy for
2–3 cycles and only patients with disease control carried on with
CRT (Huguet et al, 2007; Krishnan et al, 2007). Prospective data
from phase III trials that confirm a survival advantage for such a
treatment regimen are still lacking; however, phase II data have
shown the feasibility and tolerance of these concepts (Ko et al,
2007; Moureau-Zabotto et al, 2008). Moreover, novel innovative
CRT regimens for LAPC including newer agents (e.g. oral
fluoropyrimidines and biologicals) are currently under investiga-
tion in phase I and II clinical trials (Crane et al, 2006; Duffy et al,
2008; Kim et al, 2009; Michael et al, 2009).
In conclusion, none of the three CRT regimens investigated
in this randomised phase II trial met the protocol pre-defined
criteria for clinical efficacy (9-month OS rate 460%). The
observed median OS times were similar to those previously
reported with single-agent gemcitabine chemotherapy in LAPC.
New treatment strategies are urgently required in patients with
LAPC focusing on both an effective local disease control (eg with
the use of innovative CRT regimens) and also a distant disease
control with the use of effective systemic therapy.
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Table 4 Toxicity results according to RTOG and NCI-CTC, version 2.0 (maximum per patient)
Percentage of patients
RT-5-FU (n¼29) RT-GC (n¼31) RT-GC+GC (n¼27)
Grade Grade Grade
Toxicity 1–2 3–4 1–2 3–4 1–2 3–4
RTOG acute toxicity
Leukocytopaenia 46 4 48 52 34 62
Thrombocytopaenia 18 4 31 52 46 38
Anaemia 54 0 79 7 77 4
Upper GI tract 39 0 28 20 42 8
Lower GI tract 15 4 10 10 12 0
Skin 7 0 10 0 4 0
Non-haematological toxicity (NCI-CTC)
Fatigue 34 10 26 13 63 4
Weight loss 34 0 45 3 49 0
Diarrhoea 24 10 29 3 45 0
Nausea 62 0 74 13 89 4
Febrile neutropaenia 3 0 3 0 8 0
Infection without neutropaenia 24 7 29 3 26 0
Abbreviations: 5-FU¼5-fluorouracil; C¼cisplatin; G¼gemcitabine; RT¼radiotherapy.
Table 5 Efficacy results from selected phase II and III trials in LAPC
Treatment protocol (Reference) Phase
No. of
patients Regimen
PFS/TTP
(months)
OS
(months)
RT/cGem (Small Jr et al, 2008) II 41 RT: 36Gy, cGem: 1000mgm
 2
(days 1, 8, 15)
NA 1y-OS rate:
73%
RT/cGem-Cis + sGem (Haddock et al, 2007) II 48 RT: 50.4Gy, cGem: 30mgm
 2, cCis:
10mgm
 2 (twice weekly)
7.3 10.2
RT/cGem-Cis (Hong et al, 2008) II 41 RT: 45Gy, cGem: 1000mgm
 2 (weekly) 8.9 16.7
cCis: 70mgm
 2 (days 1, 29)
RT/cGem + sGem vs Gem (Loehrer et al, 2008) III 74 RT: 50.4Gy, cGem: 600mgm
 2, sGem:
1000mgm
 2 (both weekly) vs
Gem 1000mgm
 2 (weekly)
6.0 vs 6.7 11.0 vs 9.2*
RT/c5-FU-Cis + sGem vs Gem (Chauffert et al, 2008) III 119 RT: 60Gy, c5-FU: 300mgm
 2 per day,
cCis: 20mgm
 2 per day
NA 8.6 vs 13.0
þ
sGem: 1000mgm
 2 (weekly) vs Gem
1000mgm
 2 (weekly)
RT/c5-FU vs RT/cGem-Cis vs RT/cGem-Cis +
sGem-Cis (this study)
II 95 see Material and Methods 4.0 vs 5.6 vs 6.0 9.6 vs 9.3 vs 7.3
Abbreviations: 5-FU¼5-fluorouracil; Cis¼cisplatin; c¼concurrent chemotherapy; CRT¼chemoradiotherapy; Gem¼gem; RT¼radiotherapy; s¼sequential chemotherapy.
*P¼0.034;
+P¼0.03.
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